S-Panloc

Description

About S-Panloc Tablet

S-Panloc Tablet, manufactured by Omnica Laboratories Pvt. Ltd. and available in Nepal, contains the active ingredient Pantoprazole Sodium Sesquihydrate. This medication is a proton pump inhibitor (PPI). It works by blocking the final step of acid production in the stomach’s parietal cells, effectively reducing both normal (basal) and stimulated acid secretion.

What is S-Panloc Tablet Used For?

S-Panloc Tablet is prescribed to treat conditions caused by excessive stomach acid, including:

• Peptic ulcer disease
• H. pylori infection
• Gastro-oesophageal reflux disease (GERD)
• Zollinger-Ellison syndrome
• Oesophagitis (inflammation of the esophagus)
• Acid-related dyspepsia (indigestion)
• NSAID-associated ulceration (ulcers caused by non-steroidal anti-inflammatory drugs)
• Ulcers that are resistant to H2 receptor antagonists
• Gastrointestinal (GI) bleeding due to stress
• Prophylaxis for acid aspiration syndrome during the induction of anesthesia

Dosage Information

The appropriate dosage of S-Panloc Tablet depends on the condition being treated, as well as the patient’s age and overall health.

Adult Dosing

• Erosive Esophagitis Associated with GERD:
  • Treatment: 40 mg by mouth (PO) once daily for 8-16 weeks.
  • Maintenance of healing: 40 mg PO once daily.
  • Alternatively: 40 mg intravenously (IV) once daily for 7-10 days.
• Short-term Treatment of GERD (when oral therapy is not appropriate or possible): 40 mg as an IV infusion over 15 minutes once daily for 7-10 days. Patients should switch to oral therapy once they are able to swallow.
• Zollinger-Ellison Syndrome:
  • Oral: 40 mg PO once daily; some patients may receive up to 240 mg/day.
  • IV: 80 mg as an IV infusion every 8-12 hours for up to 7 days. Patients should switch to oral therapy once they are able to swallow.
• Peptic Ulcer Disease:
  • Duodenal ulcer: 40 mg PO once daily for 2-4 weeks.
  • Gastric ulcer: 40 mg PO once daily for 4-8 weeks.
• Elderly Patients: No dosage adjustment is typically needed.
• Hepatic Impairment: The maximum dose is 20 mg/day or 40 mg on alternate days.

Child Dosing (for Erosive Esophagitis Associated with GERD)

• Under 5 years: The safety and efficacy of S-Panloc have not been established in this age group.
• 5 years and older:
  • 15 kg to less than 40 kg: 20 mg PO once daily for up to 8 weeks.
  • 40 kg or greater: 40 mg PO once daily for up to 8 weeks.

Renal Impairment

• No dosage adjustment is needed for patients with renal impairment.

Administration Guidelines

• Controlled-release tablets: Take on an empty stomach, ideally 1 hour before meals. Swallow the tablet whole; do not chew or crush it.
• Normal release tablets: Can be taken with or without food.

IV Preparation

• For GERD with a history of erosive esophagitis (15-minute infusion): Reconstitute the vial with 10 mL of normal saline (NS). Then, further dilute this solution with 100 mL of D5W, NS, or Lactated Ringer’s (LR) solution to achieve a final concentration of 0.4 mg/mL.
• For Zollinger-Ellison syndrome:
  • 15-minute infusion: Reconstitute each vial with 10 mL of NS. Combine two vials and further dilute with 80 mL of D5W, NS, or LR to a total volume of 100 mL, resulting in a concentration of 0.8 mg/mL.
  • 2-minute injection: Reconstitute with 10 mL of NS to a final concentration of 4 mg/mL.

IV Administration

• Infuse over 15 minutes.
• The maximum infusion rate should not exceed 3 mg/minute (7 mL/minute) for GERD and 6 mg/minute (7 mL/minute) for conditions involving pathologic hypersecretion.

Important Considerations

Contraindications

Do not use S-Panloc Tablet if you are taking rilpivirine, atazanavir, or nelfinavir. It is also contraindicated during lactation.

Precautions

• Your doctor should rule out gastric malignancy before initiating treatment with S-Panloc.
• Consider zinc supplementation during IV therapy for patients who are prone to zinc deficiency.
• Use with caution during pregnancy.
• Monitoring: Your doctor will likely monitor your magnesium levels before starting and periodically during prolonged use of S-Panloc.

Interactions with Other Medications

S-Panloc Tablet can interact with various other medications, potentially altering their effects:

• Increased risk: Digoxin-induced cardiotoxic effects, hypomagnesaemia with diuretics, increased INR and prothrombin time with warfarin, and increased serum concentrations of methotrexate and saquinavir.
• Decreased absorption/bioavailability: Sucralfate can delay absorption and decrease bioavailability. It can also decrease the absorption of ketoconazole and itraconazole.
• Potentially Fatal: S-Panloc may significantly decrease the serum levels and pharmacological effects of rilpivirine, atazanavir, and nelfinavir.

Possible Side Effects

Common side effects (1-10% of patients) include:

• Headache (>4%)
• Abdominal pain (4%)
• Diarrhea (4%)
• Constipation (<4%)
• Pruritus (itching) (4%)
• Rash (4%)
• Flatulence (<4%)
• Hyperglycemia (1%)
• Nausea (1%)
• Vomiting (>4%)
• Facial edema (<4%)
• Generalized edema (<2%)
• Chest pain (4%)
• Photosensitivity (<2%)

Serious but less frequent side effects (frequency not defined) include:

• Angioedema
• Atrophic gastritis
• Anterior ischemic optic neuropathy
• Hepatocellular damage, potentially leading to hepatic failure
• Interstitial nephritis
• Pancreatitis
• Pancytopenia
• Rhabdomyolysis
• Risk of anaphylaxis
• Stevens-Johnson syndrome
• Fatal toxic epidermal necrolysis
• Erythema multiforme

Important Note

This information about S-Panloc Tablet is for general knowledge and is not intended as medical advice, diagnosis, or treatment. It should not replace the professional judgment of a healthcare provider. Always consult with your doctor or pharmacist for any health concerns or before making decisions about your medication.